revumenib (Revuforj)

From Aaushi

Jump to navigation Jump to search

^[1]^[2]

Indications

relapsed or refractory KMT2A-rearranged or NPM1-mutant acute leukemia
adults & children with relapsed/refractory NPM1-mutated AML

Adverse effects

differentiation syndrome
QTc interval prolongation & Torsades de Pointes
embryo-fetal toxicity

Mechanism of action

menin inhibitor

More general terms

small inhibitory antineoplastic agent (ib drug)

References

↑ Brooks M Novel Drug Leads to 'Impressive' Responses in Advanced Leukemia. Medscape. March 20, 2023 https://www.medscape.com/viewarticle/989871
↑ Bassett M Two Drugs Approved for NPM1-Mutated Leukemia. Approval of ziftomenib is in adults, while revumenib's extends to pediatric patients as well. MedPage Today. November 13, 2025 https://www.medpagetoday.com/hematologyoncology/leukemia/118506

Database

PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=169490859

Retrieved from "https://aaushi.info/w/index.php?title=A58041&oldid=1279586"

↑ Back to top